Belatacept for kidney transplant recipients
Editorial Group: Cochrane Renal Group
Published Online: 15 AUG 2013
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Masson P, Henderson L, Chapman JR, Craig JC, Webster AC. Belatacept for kidney transplant recipients (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD010699. DOI: 10.1002/14651858.CD010699.
- Publication Status: New
- Published Online: 15 AUG 2013
This is the protocol for a review and there is no abstract. The objectives are as follows:
The objectives of this review are to:
- Compare the relative efficacy of belatacept versus any other immunosuppressive co-intervention for preventing acute rejection and maintaining kidney transplant function, and composite kidney transplant and recipient survival.
- Compare the incidence of several adverse events: Post-transplant lymphoproliferative disorder; other malignancies; IF/TA; infective complications; deterioration in blood pressure, lipid and glycaemic control.
- Assess any variation in effects by study, intervention and recipient characteristics, including: differences in pre-transplant Epstein-Barr virus status; belatacept dosing regimen; and donor-category (living, standard criteria deceased, or extended criteria deceased).